Ali Moustapha

Interrogation of the Tricuspid Annulus by Doppler Tissue Imaging in Patients with Chronic Pulmonary Hypertension: Implications for the Assessment of Right-Ventricular Systolic and Diastolic Function

Background: Chronic pulmonary hypertension (CPHT) has a great impact on both right-ventricular (RV) systolic and diastolic properties and the assessment of those properties is not always feasible by traditional echocardiographic examination. Doppler tissue imaging (DTI) interrogation of the tricuspid annulus (TA) identifies the pattern of TA motion (TAM) and can help to assess RV function when other methods are not feasible. Aims: To determine RV systolic and diastolic function in patients with CPHT using DTI parameters of the TA. Methods: Eighty-seven patients with CPHT and 90 normal controls were studied. DTI parameters were measured including early diastolic, late diastolic and systolic velocities and time velocity integrals (TVI) of the TAM at both its lateral and medial aspect. Results: Early diastolic and systolic velocities, the ratio of early to late diastolic velocities and TVI of TAM at both lateral and medial aspects were significantly decreased in patients with CPHT compared to controls. No significant differences were seen in late diastolic velocities and TVI in both groups. Systolic velocity of the TAM at both its lateral and medial aspects significantly correlated with RV systolic function as measured by fractional RV area change. Conclusions: DTI of the TAM can be used to assess RV systolic and diastolic properties in patients with CPHT.

Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices

The most consistent procedural predictor of vascular access site complications thus far has been the intensity and duration of anticoagulant therapy during and after percutaneous coronary interventions (PCI). Several devices have been developed to aid in the closure of the femoral arteriotomy. This report describes the clinical outcome of unsuccessful deployment of femoral closure devices in a cohort of 285 consecutive patients who underwent PCI and were treated with platelet glycoprotein (GP) IIb/IIIa inhibitors. Manual femoral artery compression was used in 123 patients, Perclose in 123 patients, and AngioSeal in 39 patients. Successful homeostasis was achieved in 98.4% of patients who received manual compression, in 91.9% of the Perclose‐sealed arteriotomy, and in 84.6% of patients who received the AngioSeal closure device (P = 0.004). The incidence of vascular complications after successful deployment was 9%. Patients not achieving hemostasis with closure device or 1° manual compression developed complications in the majority of cases (> 80%; P < 0.05). By multivariate analysis (with adjustment for baseline differences), the use of AngioSeal closure device was found to be an independent risk factors leading to primary deployment failure and all access site complications (OR 2.97; 95% CI 1.5–6.0; P = 0.006). In summary, failed hemostasis by artery closure devices in patients undergoing PCI who are treated with GP IIb/IIIa inhibitors is associated with significant vascular complications. AngioSeal may be associated with a higher failure rate, while manual compression and Perclose seem to be more effective with a lower complication rate. Cathet Cardiovasc Intervent 2003;58:1–5.

Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban)

T clinical efficacy and safety of clopidogrel pretreatment in addition to glycoprotein (GP) IIb/IIIa antagonists during percutaneous coronary intervention (PCI) is unknown. This study compares the in-hospital clinical outcome of patients who received clopidogrel pretreatment before PCI with that in patients who did not receive it as adjunctive antiplatelet therapy to GP IIb/IIIa antagonists. • • • Data were collected from the Memorial Hermann Heart Center Interventional Cardiology database. We examined a consecutive series of 299 patients undergoing PCI. All patients received GP IIb/IIIa inhibitor therapy in the form of abciximab or tirofiban. Use and type of GP IIb/IIIb antagonists was at the discretion of the operator. Abciximab was given as a bolus dose of 0.25 mg/kg body weight followed by continuous infusion of 10 g/min for 12 hours. Tirofiban was given as a loading dose of 0.4 g/kg/min for 30 minutes followed by a maintenance dose of 0.1 g/kg/min for 12 to 24 hours after the procedure. All patients were taking aspirin and received a heparin bolus to achieve an activated clotting time between 250 and 300 seconds. Patients presenting to the catheterization laboratory with a developing myocardial infarction (MI) for a primary or rescue angioplasty were excluded. Patients were divided into 2 groups: those who received clopidogrel pretreatment before PCI (starting within 5 days before PCI or a loading dose of 300 mg the morning of the day of the procedure at the discretion of the primary operator, group I), and those who received aspirin alone (group II) with clopidogrel (300 mg loading dose and 75 mg/day for 1 month) given after stent deployment. Therapy with clopidogrel (75 mg/day) was continued for 1 month in both groups if the stent was deployed during the procedure. Coronary angioplasty and intracoronary stent implantation were performed using standard percutaneous techniques. Balloon size was selected to match the reference vessel diameter obtained from on-line angiographic analysis (1.1:1 balloon/artery ratio). Different types of stents were used (excluding open coil type). After stent implantation, high-pressure balloon dilatation was performed for angiographic optimization. Intravascular ultrasonography–guided coronary stenting was not performed in most patients. Each operator relied on his own judgment or on other objective measurements, such as online quantitative coronary angiography, to assess PCI results. On completion of the procedure, patients were moved to a monitored unit and the arterial sheath was removed. Successful PCI was defined as final residual stenosis within the treated lesion of 20%, with achievement of Thrombolysis In Myocardial Infarction grade 3 flow, without in-lab occurrence of death, MI, or a complication requiring immediate coronary revascularization. A major adverse cardiac event was defined as any 1 of the following: (1) Q-wave or non–Q-wave MI, (2) need for urgent repeat target vessel revascularization, or (3) cardiovascular death that occurred during the period of hospitalization after the index coronary procedure. Postprocedural MI was defined as the occurrence of typical ischemic chest pain of 30 minutes duration with a creatine kinase elevation of 3 times the upper limit of normal with an associated increase in the MB fraction. There was no routine protocol for acquisition of postprocedure creatine kinase. All postprocedural cardiac enzymes were obtained for suspected recurrent myocardial ischemia, manifested by recurrent postprocedural chest pain, hemodynamic instability, or new electrocardiographic changes of ischemia. Urgent target vessel revascularization was defined as a repeat PCI or coronary artery bypass grafting of the index artery due to presumed recurrent ischemia manifested by recurrent angina, arrhythmias, or hemodynamic compromise. Adverse effects of therapy were recorded and compared between the 2 groups. These consist of major bleeding and thrombocytopenia. Major bleeding was defined as bleeding requiring transfusion of blood products or precipitating hemodynamic compromise. Intracerebral hemorrhage of any extent was considered a major adverse effect of therapy. Thrombocytopenia was defined as platelet count 100,000/mm. Chi-square and Fischer exact tests were used for analysis of categorical variables when appropriate, and Student t testing was used for analysis of continuous variables. Multivariate logistic regression analysis was performed to determine significance of variables related to an in-hospital major adverse cardiac From the Cardiology Division, University of Texas Medical School and Hermann Heart Center, Memorial Hermann Hospital, Houston, Texas. Dr. Rosales’ address is: Division of Cardiology, University of Texas Health Science Center-Houston, PO Box 20708, Houston, Texas 77225-0708. Manuscript received March 29, 2001; revised manuscript received and accepted May 30, 2001.

Echocardiographic Evaluation of Left-Ventricular Diastolic Function in Patients with Chronic Pulmonary Hypertension

Different patterns of left-ventricular (LV) diastolic dysfunction were reported in patients with pulmonary hypertension (PHT). There are no data regarding the relationship between the severity of PHT and LV diastolic dysfunction. In order to determine the severity of PHT at which LV diastolic dysfunction occurs and to identify its pattern, we studied by Doppler echocardiography 120 patients with PHT (57 with severe PHT and 63 with mild or moderate PHT) and compared them with 75 normal controls. Systolic pulmonary artery pressure (SPAP) was measured by tricuspid regurgitant jet method and the usual transmitral LV diastolic indices were recorded. LV diastolic dysfunction of impaired relaxation type is most commonly seen in patients with severe PHT. No differences were observed between patients with mild and moderate PHT regarding LV diastolic function. A SPAP ≧60 mm Hg is needed to induce changes in the LV diastolic filling pattern.

Successful treatment of coronary artery perforation in an abciximab-treated patient by microcoil embolization.

We describe a case of type 2 coronary artery perforation in a 73‐year‐old man undergoing coronary artery rotablation and stenting with abciximab therapy. The coronary artery perforation was successfully treated by coil embolization with Trufill pushable coils made from platinum alloy and synthetic fibers to promote maximum thrombogenicity. Cathet. Cardiovasc. Intervent. 51:487–489, 2000.

Combined cutting balloon angioplasty and intracoronary beta radiation for treatment of in‐stent restenosis: Clinical outcomes and effect of pullback radiation for long lesions

Intracoronary beta (β) radiation decreases the incidence of target lesion revascularization after percutaneous intervention (PCI) for in‐stent restenosis (ISR). Cutting balloon (CB) angioplasty may also be superior to other percutaneous techniques for the treatment of ISR. We sought to study the outcomes of patients with ISR who underwent both CB angioplasty and intracoronay β radiation and compare them to patients with ISR who underwent other PCI techniques without concomitant radiation. We also sought to evaluate the safety and efficacy of pullback intracoronary β radiation for the treatment of long ISR lesions. Between January 2001 and November 2001, 102 patients (mean age = 55 ± 13 years) with ISR underwent both CB angioplasty and intracoronay β radiation. β radiation was delivered using the Beta Cath (Novoste) 30 mm system, and pullback radiation was performed in 41 patients. A comparison group included a total of 393 patients with ISR who underwent other PCI techniques without concomitant intracoronary radiation therapy. Follow‐up was obtained in 99 patients (97%) in the CB angioplasty with intracoronary radiation group and 377 patients (96%) in the comparison group. At follow‐up, both target vessel revascularization (TVR) and major adverse cardiovascular events (MACE) occurred significantly less in the CB angioplasty with intracoronary radiation group than in the comparison group (7% vs. 18% for TVR, and 14% vs. 24% for MACE; P < 0.05 for both). In the pullback radiation group, TVR was performed in five patients (12%), and MACE occurred in eight patients (20%). A combination of CB angioplasty and intracoronay β radiation for ISR seems to yield low rates of subsequent target vessel revascularization and adverse cardiac events. In addition, pullback β radiation using the Beta Cath (Novoste) 30 mm system is safe and can be used to treat long ISR lesions effectively. Further randomized trials are needed to confirm these findings. Cathet Cardiovasc Intervent 2002;57:325–329.

Revascularization interventions for ischemic heart disease.

Coronary artery bypass grafting and percutaneous transluminal coronary angioplasty are now well established methods of myocardial revascularization. The choice of a method of revascularization depends on several clinical and angiographic parameters. Patients who derive the greatest benefit from coronary artery bypass grafting are those with left main coronary artery disease or those with three-vessel disease with left ventricular impairment. Patients with single-vessel disease achieve more symptomatic relief with coronary angioplasty than with medical therapy alone, but with no improvement in long-term mortality. In nondiabetic patients with multiple-vessel disease, angioplasty and bypass grafting likely yield similar results, and the choice of revascularization technique rests on weighing the more invasive nature of bypass grafting against the need for additional future revascularizations with angioplasty. Diabetic patients with multiple-vessel disease seem to achieve better outcomes with bypass grafting. Minimally invasive bypass surgery is an evolving technique. It is less invasive in nature but its applications are limited, and its advantages over traditional bypass grafting have not yet been shown. Stenting now plays a major role in percutaneous revascularization and is performed in more than two thirds of all interventional procedures. It improves both the short-term and the long-term outcomes of coronary angioplasty. Other novel percutaneous techniques such as directional or rotational atherectomy, laser angioplasty, or thrombectomy devices have not shown convincing superiority over coronary angioplasty alone. Transmyocardial laser revascularization can be performed surgically or percutaneously and may be beneficial in patients with angina refractory to traditional revascularization procedures.

Percutaneous closure of patent foramen ovale guided by intracardiac echocardiography and performed through the transfemoral approach in the presence of previously placed inferior vena cava filters: A case series

We present three patients with cryptogenic stroke who underwent transcatheter closure of a patent foramen ovale. All patients have had history of deep venous thrombosis and pulmonary embolism with placement of inferior vena caval filters. The patients were not initially considered suitable candidates for the procedure because of risk of dislodgment of previously implanted inferior vena cava filter. Catheter Cardiovasc Interv 2004;63:242–246.

Causes of early reintervention after successful coronary artery stenting.

Acute reintervention was performed in 26 of 1,620 patients after coronary stenting (1.6%). Half of the patients had stent thrombosis and the other half residual anatomic problems. The mean time for reintervention was shorter in patients with stent thrombosis. All patients with stent thrombosis had a sudden recurrence of chest pain. Electrocardiographic changes were more common with stent thrombosis. Composite end point occurred in 10 patients (77%) with stent thrombosis versus 5 (39%) in the other group (p = 0.04).

Quantitative relationship between severity of pulmonary hypertension and LV diastolic function has been established

We read with interest the article entitled “Correlation of Left Ventricular Filling Characteristics With Right Ventricular Overload and Pulmonary Artery Pressure in Chronic Thromboembolic Pulmonary Hypertension” published in the July 17, 2002, issue of the Journal [(1)][1]. Dr. Mahmud and his